Clinical laboratory of Shandong Cancer Hospital and Institute

laboratory of, China

Clinical laboratory of Shandong Cancer Hospital and Institute

laboratory of, China

Time filter

Source Type

Zeng Q.,Clinical laboratory of Shandong Cancer Hospital and Institute | Zeng Q.,University of Jinan | Liu M.,Clinical laboratory of Shandong Cancer Hospital and Institute | Zhou N.,Clinical laboratory of Shandong Cancer Hospital and Institute | And 3 more authors.
Clinica Chimica Acta | Year: 2016

Background: Human epididymis protein 4 (HE4) had been shown to be an ideal biomarker in ovarian cancer. However, there were fewer reports on its application in lung cancer. We explored the diagnostic value of serum HE4 as a biomarker in early lung cancer by comparing it with other biomarkers. Methods: 162 individuals including 112 cases of lung cancer at early stage and 50 healthy people as controls were enrolled. The serum concentrations of biomarkers were determined with the Roche Elecsys assays. Results: In comparison to the other biomarkers such as carcinoembryonic antigen (CEA), neuron-specific-enolase (NSE), serum cytokeratin 19 fragment (CYFRA 21-1) and progastrinreleasing peptide (proGRP), serum HE4 was one of the biomarkers with the highest sensitivity (43.8%) and specificity (95.0%) for early lung cancer diagnosis. In terms of histological results, serum HE4 was the best biomarker both in adenocarcinoma (AC) and squamous carcinoma (SC), and serum proGRP was the best in small cell lung cancer (SCLC). The combination of proGRP, NSE and HE4 could determine the histological type of lung cancer with a very high accuracy of 93.8%. Conclusions: These findings suggested that serum HE4 was a better biomarker in early lung cancer than other frequently-used biomarkers. © 2016 Elsevier B.V.

Loading Clinical laboratory of Shandong Cancer Hospital and Institute collaborators
Loading Clinical laboratory of Shandong Cancer Hospital and Institute collaborators